GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
116 articles in GLP-1 & Metabolic · page 8 of 10
GLP-1s and Cognitive Health: Early Signals
Researchers studied GLP-1s in the brain, and the largest Alzheimer's trials came back negative. What the early signals were, and what remains.
Read →Tirzepatide for Heart Failure: The SUMMIT Trial
Tirzepatide cut heart-failure events in obesity-related HFpEF in the SUMMIT trial. What that result does and doesn't show.
Read →GLP-1s and 'Food Noise': The Science of Reduced Cravings
The most striking patient-reported GLP-1 effect may point to the brain's reward circuitry, not just the gut. What that implies.
Read →Will GLP-1s Work for You? Predicting Response
Response varies widely. What controlled trials say about who loses the most — and the real limits of predicting it upfront.
Read →GLP-1s and Exercise: A Better-Together Story
GLP-1 weight loss includes lean mass. Why resistance training changes what kind of weight you lose, and what the trials measured.
Read →GLP-1s in Type 2 Diabetes vs Obesity: Different Goals
Same drug class, different endpoints, doses, and expectations depending on why it was prescribed. How diabetes and obesity use diverge.
Read →Rebound Weight After GLP-1s: What Studies Show
STEP 1's extension found people regained two-thirds of lost weight a year after stopping semaglutide. The numbers and what they mean.
Read →The Incretin Effect, Explained
Why oral glucose triggers far more insulin than the same glucose given intravenously, and what happens to that signal in type 2 diabetes.
Read →GLP-1s and Pancreatitis: What the Data Says
A long-standing concern examined against pooled trial meta-analyses. The signal, if real, looks small — here are the numbers.
Read →GLP-1s and Gastroparesis: Weighing the Risk
Slowed stomach emptying is both the mechanism and the side effect. What cohort data and anesthesia guidance actually show.
Read →GLP-1 Dosing and Titration: Why Slow Wins
Wegovy escalates over 16+ weeks for a reason: slow titration trades a slower ramp for far better tolerability. The evidence.
Read →GLP-1s and Thyroid Cancer: Reading the Black-Box Warning
A 437,000-person BMJ cohort found no clear thyroid-cancer signal. The black-box warning rests on rodent data, not human harm.
Read →